Results from a large, real-world study of asthma patients found that digital health technology can improve patient outcomes and inform city-planning policy, Propeller Health touted this month. The company teamed up with local government in Louisville, Kentucky and a nonprofit group to assess how environmental conditions can influence asthma symptoms using connected inhalers and a […]
JDRF tackles insulin consistency, potency at U.S. pharmacies
JDRF is teaming up with the American Diabetes Association and the Leona M. and Harry B. Helmsley Charitable Trust to support research evaluating the consistency and potency of insulin purchased at retail pharmacies in the U.S. The group called for proposals from analytical laboratories to assess the activity of insulin in vials and cartridges, looking […]
Mimetas lands $21m for organ-on-a-chip tech
Mimetas said today that it raised $20.5 million in a Series B round from a syndicate of investors in Asia and Europe. The Netherlands-based company intends to use its newly-acquired funds to support global commercialization efforts for its OrganoPlate organ-on-a-chip drug-testing platform. Mimetas added that it hopes to broaden its product portfolio and establish tissue […]
AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers
Pharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today. Owlstone’s ReCiva breath sampler, which has CE Mark clearance in the E.U., captures volatile organic compounds in a patient’s breath. A VOC profile can […]
Embolx wins $2m NIH grant for pressure-directed embolization therapy
Embolx said today that it landed a $2 million grant from the National Cancer Institute to fund development of its next-generation Sniper balloon occlusion microcatheter. The Sunnyvale, Calif.-based medical device company has developed a drug-delivery system that administers therapies into targeted areas of the body by controlling pressure. Embolx’s Sniper balloon is designed to treat cancerous […]
NIH launches $1.1B initiative to accelerate treatment options for opioid addiction
At the 2018 National Rx Drug Abuse and Heroin Summit today, National Institutes of Health director Dr. Francis Collins announced that the agency is launching the ‘Helping to End Addiction Long-term’ initiative. The NIH expects to spend nearly $1.1 billion in 2018 on research dedicated to expanding treatment options for people who are addicted to […]
Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Eli Lilly (NYSE:LLY) plans to put $473 million on the table to fund a collaboration with Cambridge, Mass.-based startup Sigilon Therapeutics, the insulin-maker reported today. The goal of the newly-established partnership is to develop encapsulated cell therapies to treat Type I diabetes. In patients who suffer from Type I diabetes, pancreatic beta cells are killed off […]
NIH study finds islet transplants improve quality of life for people with Type I diabetes
A Phase III trial funded by the National Institutes of Health found that quality of life for people with type I diabetes improved dramatically following transplantation of insulin-producing pancreatic islets, according to data published this week in the journal Diabetes Care. The 48-patient trial involved participants with hypoglycemia unawareness, a condition that renders them unable to […]
Novartis, Harvard team up to develop immunotherapy drug-delivery systems
Novartis (NYSE:NVS), Harvard University and the Dana-Farber Cancer Institute are teaming up to develop the next generation of implantable and injectable biomaterials designed to delivery immunotherapies, the group reported today. Researchers from Harvard’s Wyss Institute for Biologically Inspired Engineering have worked for years to create systems that provide targeted, sustained delivery of immuno-oncology products. Now, Novartis […]
MIT study reveals the problem with bioresorbable stents
Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX). But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb […]
- 1
- 2
- 3
- …
- 38
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn